Evidence map›Paper›PMID 41234967›Full record

ArticleCureus2025

Erythroderma and Bullae in a Psoriatic Patient: Navigating Diagnostic Bias.

Julia R Nadelmann, Emily R Nadelmann, Caroline Halverstam, Benedict Wu

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Coexistence of Erythrodermic Psoriasis and Bullous Pemphigoid: A Case Report.Clinical, cosmetic and investigational dermatology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Julia R NadelmannDermatology, Albert Einstein College of Medicine, Bronx, USA.
Emily R NadelmannDermatology, Albert Einstein College of Medicine, Bronx, USA.
Caroline HalverstamDermatology, Albert Einstein College of Medicine, Bronx, USA.
Benedict WuDermatology, Albert Einstein College of Medicine, Bronx, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Erythroderma, defined as erythema and scaling involving almost the entire body surface area, is a potentially life-threatening dermatologic condition that may be idiopathic or secondary to inflammatory diseases such as psoriasis or atopic dermatitis, drug reactions, autoimmune blistering disorders, or malignancy. Bullous pemphigoid (BP), a common autoimmune blistering disorder in older adults, rarely presents with erythroderma, and its coexistence with psoriasis is uncommon. We report the case of a 62-year-old man with long-standing psoriasis who presented with one month of progressive pruritus and erythroderma following recent furosemide use, with worsening of his eruption despite a prednisone taper prescribed at an outside urgent care. He was initially treated with cyclosporine for a presumed psoriasis flare but developed numerous tense bullae shortly after admission. Biopsies obtained at presentation demonstrated subepidermal bullae with eosinophils on hematoxylin and eosin staining, and linear IgG and C3 along the basement membrane on direct immunofluorescence, confirming BP. Discontinuation of furosemide and initiation of systemic corticosteroids, followed by adjunctive therapies, led to complete remission. This case highlights the diagnostic challenges of erythroderma and the risk of anchoring bias in patients with pre-existing dermatoses. A thorough medication history, early biopsy, and immunopathologic evaluation are essential to avoid delays in recognizing atypical presentations of BP.

Indexed as

autoimmune blistering diseasesbullous pemphigoidcognitive biasdifferential diagnosiserythrodermapsoriasis

Identifiers

PMID41234967
PMCPMC12606679

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.